Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

100 results about "High affinity antibody" patented technology

Anti-HA High Affinity is a monoclonal antibody to the HA-peptide (clone 3F10). Anti-HA High Affinity recognizes the HA peptide sequence (YPYDVPDYA), derived from the influenza hemagglutinin protein.

Transgenic mammals having human Ig loci including plural VH and VK regions and antibodies produced therefrom

InactiveUS7064244B2Reduced development and maturation of B-cellsEfficient productionAntipyreticAnalgesicsHuman animalMammal
The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (VH and Vκ) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.
Owner:ABQENIX INC

Method of producing a plurality of isolated antibodies to a plurality of cognate antigens

The present invention relates to a method for producing high affinity antibodies that are antigen-specific. The method involves binding a plurality of antibody-producing B-cells from a mammal to a plurality of cognate antigens; sorting the bound antibody-producing B-cell and cognate antigen; amplifying nucleic acid sequences encoding each antibody, or fragment thereof, from the B-cells; and expressing the each antibody in a protein expression system. Antibodies produced in this manner are useful in diagnostic and therapeutic applications.
Owner:MONTECITO BIO SCI

Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections

Disclosed are novel polyclonal antibodies, which target respiratory syncyticilal virus (RSV), and novel high affinity antibody molecules reactive with RSV. The polyclonal antibodies may comprise antibody molecules which are reactive with both RSV protein F and RSV protein G, and preferably the polyclonal antibodies target a variety of epitopes on these proteins. The single antibody molecules of the invention are shown to exhibit affinities which provide for dissociation constants as low as in the picomolar range. Also disclosed are methods of producing the antibodies of the invention as well as methods of their use in treatment for RSV infection.
Owner:SYMPHOGEN AS

High affinity antibodies against HMGB1 and methods of use thereof

InactiveUS20060099207A1Reduce bone loss and/or cartilage damageAntibacterial agentsAntibody mimetics/scaffoldsReperfusion injuryAllograft rejection
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
Owner:MEDIMMUNE LLC

Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents

Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibodies, and an additional anti-inflammatory agent, especially corticosteroids, as well as anti-inflammatory antibodies, especially anti-interleukin-6. Also disclosed are methods of using such compositions to treat and / or prevent respiratory diseases. Such compositions may optionally contain other non-antibody anti-viral agents.
Owner:AREXIS +1

Ultra high affinity neutralizing antibodies

Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and / or treat disease, especially virus-induced diseases, are also disclosed.
Owner:MEDIMMUNE LLC

TGF-β binding antibodies

The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.
Owner:ELI LILLY & CO

Protofibril selective antibodies and the use thereof

The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (Aβ) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or mutations thereof, retaining high Fc receptor binding and low C1(C1q) binding, effective in clearance of Aβ protofibrils and with reduce risk of inflammation.
Owner:BIOARCTIC AB

Ultra high affinity neutralizing antibodies

Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and / or treat disease, especially virus-induced diseases, are also disclosed.
Owner:MEDIMMUNE LLC

Monoclonal antibodies directed to cd20

The invention provides antibody to canine or feline or equine antigens. Specifically, antibodies directed to canine CD20 which have been caninized or felinized are provided. Also provided are methods for preparing high affinity antibodies to canine and feline CD20 as well as methods for treating B cell disorders in companion animals.
Owner:ARATANA THERAPEUTICS

System and methods for detection of Bacillus anthracis related analytes in biological fluids

The invention provides a heterogeneous immunoassay for detection of antibodies and antigens based on specific antigen-antibody immune complex formation with multiple antigen-bearing conjugate components. The invention further provides means for optimizing the assay format for the detection of both low and high-affinity antibodies, and provides means for quantitative detection of both antibody and the corresponding antigen present in a sample. In preferred embodiments, the invention can be practiced to detect presence in biological fluid samples of antibodies to Bacillus anthracis related antigens.
Owner:IMMUNETICS

Protofibril selective antibodies and the use thereof

The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (Aβ) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or mutations thereof, retaining high Fc receptor binding and low C1(CIq) binding, effective in clearance of Aβ protofibrils and with reduce risk of inflammation.
Owner:BIOARCTIC AB

Method for preparing anti-MIF antibodies

The specification provides methods of preparing high-affinity antibodies to a macrophage migration inhibitory factor (MIF) in animals in which the MIF gene has been homozygously knocked-out (MIF− / −). Also provided are methods of preparing hybridomas which produce the anti-MIF antibodies, methods of administering the antibodies to treat inflammatory or cancerous conditions and / or diseases modulated by MIF, as well as compositions comprising said high-affinity anti-MIF antibodies.
Owner:BAXALTA GMBH

High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies

The present embodiments are related to high-affinity antibodies directed to IL-8, methods of making and characterizing such antibodies and uses of such antibodies. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and / or complementarity determining regions (CDR's), are provided.
Owner:AMGEN FREMONT INC

High affinity fully human monoclonal antibodies to interleukin-8

The present embodiments are related to high-affinity antibodies directed to IL-8, methods of making and characterizing such antibodies and uses of such antibodies. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and / or complementarity determining regions (CDR's), are provided.
Owner:AMGEN FREMONT INC

High affinity antibodies against HMGB1 and methods of use thereof

InactiveUS7585504B2Reduce bone loss and/or cartilage damageAntibacterial agentsAntibody mimetics/scaffoldsReperfusion injuryAllograft rejection
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
Owner:MEDIMMUNE LLC

Systems and methods for detection of analytes in biological fluids

The invention provides a heterogeneous immunoassay for detection of antibodies and antigens based on specific antigen-antibody immune complex formation with multiple antigen-bearing conjugate components. The invention further provides means for optimizing the assay format for the detection of both low and high-affinity antibodies, and provides means for quantitative detection of both antibody and the corresponding antigen present in a sample.
Owner:IMMUNETICS

Monoclonal antibodies directed to cd20

The invention provides antibody to canine or feline or equine antigens. Specifically, antibodies directed to canine CD20 which have been caninized or felinized are provided. Also provided are methods for preparing high affinity antibodies to canine and feline CD20 as well as methods for treating B cell disorders in companion animals.
Owner:ARATANA THERAPEUTICS

Antibody library of bacteriophages and applications in immunoassay of pesticide residue

The invention relates to a phage antibody library which assembles an ScFv gene fragment between Restriction Enzyme cutting sites of SfiI and NotI of a pCANTAB5E carrier. The phage antibody library is characterized in that the ScFv gene fragment can be affinitive and enriched with antigens of 16-membered macrolide agricultural chemicals to form a soluble single-chain antibody and the phage antibody library is applied to immunoassay of pesticide residue. The phage antibody library has the advantages that the antibody with high affinity can be obtained without animal immunization, the test period is short, the antibody library is the phage antibody library which takes small molecular milbemycin oxime of a 16-membered macrolide generic structure as immunogen to construct, the antibody library theoretically can directly obtain a specific antibody library of 16-membered macrolide compound through screening, the screening flux is high, the efficiency is high, the specificity is strong, and the affinity selecting range is wide, so that the phage antibody library has wide application prospect in the aspects such as agricultural chemical antibody preparation, testing technique development and the like.
Owner:JIANGSU ACADEMY OF AGRICULTURAL SCIENCES

Recombinant antibodies for treatment of respiratory syncytial virus infections

Disclosed are novel polyclonal antibodies, which target respiratory syncyticilal virus (RSV), as well as novel high affinity antibody molecules reactive with RSV. The polyclonal antibodies may comprise antibody molecules which are reactive with both RSV protein F and RSV protein G, and preferably the polyclonal antibodies target a variety of epitopes on these proteins. The antibody molecules of the invention have shown superior efficacy in vitro and / or in vivo. Also disclosed are methods of producing the antibodies of the invention as well as methods of their use in treatment or prevention ofRSV infection.
Owner:SYMPHOGEN AS

High affinity antibodies against hmgb1 and methods of use thereof

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
Owner:CORNERSTONE THERAPEUTICS +1

High affinity antibody antagonists of interleukin-13 receptor alpha 1

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.
Owner:CSL LTD

High-affinity antibody and method for manufacturing the same

A method for manufacturing a high-affinity antibody including purifying an antibody to which a treatment of reducing the affinity for an antigen is not applied by a temperature responsive protein A medium, in which dissociation constant (KD value) to an antigen is smaller than the KD value of an antibody purified by an acid elution type protein A medium.
Owner:ASAHI KASEI MEDICAL CO LTD +1

Anti-sildenafil specific antibody

The invention provides a preparation method of a sildenafil artificial antigen and antibody, and relates to a preparation method of an artificial hapten, antigen and antibody maximizing the retention of a sildenafil structure. A sildenafil hapten prepared by a chemical synthesis method and a carrier KLH protein are connected and synthesized into an artificial antigen; and an antibody is prepared by the following steps: immunizing animals with the artificial antigen, taking blood, separating out antiserum and purifying. By designing and synthesizing the hapten and artificial antigen having a sildenafil structure, the invention highlights the molecule-specific antigenic determinant, overcomes difficulties in chemical synthesis, and produces the high-affinity antibody through animal immunization inducement. Compared with other similar methods, the invention has the characteristics of specificity, sensitivity, accuracy, high speed, convenience, low cost and the like; and the designed and synthesized hapten lays a foundation for the preparation of the antibody having favorable specificity.
Owner:TIANJIN UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products